Report Finds Rise In 'Pay for Delay' Patent Settlements

Patent dispute settlements between brand-name and generic drug makers jumped sharply in the past year, the Federal Trade Commission has found in a new study, warning that such deals may be anticompetitive.

This article requires premium access

This article requires premium access to The Legal Intelligencer. Please sign in or subscribe to read the full text.